Life threatening manifestations of connective tissue diseases and vasculitides


Authors: J. Vymětal;  P. Horák;  M. Skácelová
Authors‘ workplace: III. interní klinika, nefrologická, revmatologická, endokrinologická, FN a LF UP Olomouc
Published in: Čes. Revmatol., 23, 2015, No. 3, p. 100-113.
Category: Review Article

Overview

Rheumatic diseases may be presented at onset or in the course of diseases by acute serious illness, even life threatening and requiring admission to intensive care unit. The spectrum of symptoms and organs involvement is very wide, so as it corresponds to systemic character of diseases, which are the primary domain of rheumatology, but it also places high demands on knowledge of possible differential diagnosis of doctors working at intensive wards. This article gives an overview of most acute situation, which physicians can meet in patients with systemic diseases, including lupus erythematosus, antiphospolipid syndrome, systemic scleroderma, dermatomyositis/polymyositis and individual types of vasculitides group.

Key words:
Life-threatening events, SLE, antiphospholipid syndrome, scleroderma, idiopatic myositis, vasculitis


Sources

1. Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 1988; 319(13): 817–23.

2. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14(9): 683–6.

3. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74(3): 275–84.

4. Smržová A, Horák P, Skácelova M, Žurek M, Fryšáková L, Vymětal J, et al. Cardiovascular events in patients with systemic lupus erytematodes. Cor vasa [serial online] 2014 Mar 24; [Cited 2014 October 20]; 56: e145-e152 Available from: http://www.sciencedirect.com/science/article/pii/S0010865014000277

5. Horák P, Ciferská H, Krajsová B. Orgánové manifestace revmatických chorob. In: Pavelka K, Vencovský J, Horák P, Šenolt L, Mann H, Štěpán J, et al (eds). Revmatologie. Praha: Maxdorf-Jessenius; 2012. p. 106–37.

6. Martinez-Martinez MU, Abud-Mendoza C. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus. Clinical manifestations, treatment, and prognosis. Reumatol Clin 2014; 10(4): 248–53.

7. Martinez-Taboada VM, Blanco R, Armona J, Fernandez-Sueiro JL, Rodriguez-Valverde V. Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity? Lupus 1995; 4(4): 259–62.

8. Abramson SB, Dobro J, Eberle MA, Benton M, Reibman J, Epstein H, et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 1991; 114(11): 941–7.

9. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL et al. Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions. Neurology 2002; 58(8): 1214–20.

10. Koskenmies S, Vaarala O, Widen E, Kere J, Palosuo T, Julkunen H. The association of antibodies to cardiolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipoprotein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus. Scand J Rheumatol 2004; 33(4): 246–52.

11. Sneddon IB. Cerebrovascular lesions and livedo reticularis. Br J Dermatol 1965; 77: 180–5.

12. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006; 15(4): 191–7.

13. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69(12): 2074–82.

14. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71(11): 1771–82.

15. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15(2):241–50.

16. Hughson MD, Nadasdy T, McCarty GA, Sholer C, Min KW, Silva F. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis 1992; 20(2): 150–8.

17. Dhingra S, Qureshi R, Abdellatif A, Gaber LW, Truong LD. Tubulointerstitial nephritis in systemic lupus erythematosus: innocent bystander or ominous presage. Histol Histopathol 2014; 29(5): 553–65.

18. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991; 34(12): 1538–45.

19. Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol 2012; 8(5): 439–53.

20. Horák P, Tegzová D, Závada J, Olejárová M, Skácelová M, Smržová A, et al. Doporučení České revmatologické společnosti pro diagnostiku a sledování nemocných se systémovým lupus erythematodes. Čes Revmatol 2013; 21(2): 59–70.

21. Horák P, Tegzová D, Závada J, Olejárová M, Skácelová M, Smržová A, et al. Doporučení České revmatologické společnosti pro léčbu nemocných se SLE. Čes Revmatol 2013; 21(2): 110–122.

22. Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2014; 10(2): 97–107.

23. Dall'era M, Chakravarty EF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep 2011; 13(4): 308–16.

24. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014; 53(8):1470–6.

25. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4(2): 295–306.

26. Ruffatti A, Salvan E, Del Ross T, Gerosa M, Andreoli L, Maina A, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study Thromb Haemost. 2014; 112(4):727–35.

27. Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol 2014; 3(1): 9–17.

28. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157(1): 47–58.

29. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 2011; 20(2): 206–218.

30. Berman H, Rodríguez-Pintó I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12(11): 1085–90.

31. The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 118: antiphospholipid syndrome. Obstet Gynecol 2011; 117(1): 192–9.

32. Di Prima FAF, Valenti O, Hyseni E, Giorgio E, Faraci M, Renda E, et al. Antiphospholipid Syndrome during pregnancy: the state of the art. J Prenat Med. 2011; 5(2): 41–53.

33. Bečvář R, Soukup T, Štork J, Suchý D, Němec P, Jansa P, et al. Doporučení České revmatologické společnosti pro diagnostiku systémové sklerodermie. Čes Revmatol 2014; 22(2): 51–68.

34. Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger TA Jr. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005; 32(4): 649–55.

35. Denton CP, Lapadula G, Mouthon L, Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 2009; 48(Suppl 3): S32–5.

36. Batal I, Domsic RT, Medsger TA, Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol [serial on the internet]. 2010 Jul 28; [Cited 2014 October 20]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958499/

37. Mouthon L, Bussone G, Berezné A, Noël LH, Guillevin L. Scleroderma renal crisis. J Rheumatol 2014; 41(6): 1040–8.

38. Steen VD. Kidney involvement in systemic sclerosis. Presse Med 2014; 43(10 Pt 2): e305-14. Available from: http://www.em-consulte.com/article/928057/article/kidney-involvement-in-systemic-sclerosis

39. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37(9):1283–9.

40. Luo Y, Xiao R. Interstitial Lung Disease in Scleroderma: Clinical Features and Pathogenesis. Rheumatology 2011 doi:10.4172/2161-1149. S1-002. Available from: http://omicsonline.org/interstitial-lung-disease-in-scleroderma-clinical-features-and-pathogenesis-2161-1149.S1-002.pdf

41. Wells AU. Interstitial lung disease in systemic sclerosis. Presse Med 2014; (10 Pt 2):e329–43.

42. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73(7):1340–9.

43. Jansa P, Becvar R, Ambroz D, Palecek T, Tomcik M, Skacelova S, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clin Rheumatol 2012, 31(3): 557–61.

44. Aschermann M, Jansa P. Medikamentózní léčba plicní arteriální hypertenze v roce 2014. Vnitr Lek 2014; 60(4): 282–8.

45. Hallowell RW, Ascherman DP, Danoff SK. Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med 2014; 35(2): 239–48.

46. Maldonado F, Patel RR, Iyer VN, Yi ES, Ryu JH. Are respiratory complications common causes of death in inflammatory myopathies? An autopsy study. Respirology 2012; 17(3): 455–60.

47. Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One [on the internet] 2014 Jun 6; [cited 2014 Oct 20]; Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048238/?report=classic

48. Hruskova Z, Casian AL, Konopasek P, Svobodova B, Frausova D, Lanska V, et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. Scand J Rheumatol. 2013; 42(3): 211–4.

49. Niles JL, Böttinger EP, Saurina GR, Kelly KJ, Pan G, Collins AB, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996; 156(4): 440–5.

50. Capizzi SA, Specks U. Does infection play a role in the pathogenesis of pulmonary vasculitis? Semin Respir Infect 2003; 18(1): 17–22.

51. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78(1): 26–37.

52. Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy 2013; 68(3): 261–73.

53. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42(3): 421–30.

54. Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture's disease (anti-GBM). J Autoimmun 2014; 48–49:108–12.

55. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E. French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84(5): 313–22.

56. Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002; 13(5): 1271–8.

57. Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117(7): 573–7.

58. Zaidan M, Mariotte E, Galicier L, Arnulf B, Meignin V, Vérine J, et al. Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis. Ann Intensive Care. 2012; 2(1):31–9.

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account